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Aim Arrhythmogenic cardiomyopathy (ACM) is a genetic disorder mainly due to mutations in desmosomal genes,
characterized by progressive fibro-adipose replacement of the myocardium, arrhythmias, and sudden death. It
is still unclear which cell type is responsible for fibro-adipose substitution and which molecular mechanisms
lead to this structural change. Cardiac mesenchymal stromal cells (C-MSC) are the most abundant cells in the
heart, with propensity to differentiate into several cell types, including adipocytes, and their role in ACM is un-
known. The aim of the present study was to investigate whether C-MSC contributed to excess adipocytes in pa-
tients with ACM.
Methods
and results
We found that, in ACM patients’ explanted heart sections, cells actively differentiating into adipocytes are of mes-
enchymal origin. Therefore, we isolated C-MSC from endomyocardial biopsies of ACM and from not affected by
arrhythmogenic cardiomyopathy (NON-ACM) (control) patients. We found that both ACM and control C-MSC
express desmosomal genes, with ACMC-MSC showing lower expression of plakophilin (PKP2) protein vs. controls.
Arrhythmogenic cardiomyopathy C-MSC cultured in adipogenic medium accumulated more lipid droplets than
controls. Accordingly, the expression of adipogenic genes was higher in ACM vs. NON-ACM C-MSC, while expres-
sion of cell cycle and anti-adipogenic genes was lower. Both lipid accumulation and transcription reprogramming
were dependent on PKP2 deficiency.
Conclusions Cardiac mesenchymal stromal cells contribute to the adipogenic substitution observed in ACM patients’ hearts. More-
over, C-MSC from ACM patients recapitulate the features of ACM adipogenesis, representing a novel, scalable, patient-
specific in vitro tool for future mechanistic studies.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Arrhythmogenic cardiomyopathy † Mesenchymal stromal cells † Adipogenesis † Fibrofatty substitution †
Plakophilin2 † Plakoglobin
* Corresponding author. Tel: +39 02 5800 2026, Fax: +39 02 5800 2342, Email esommariva@ccfm.it
† These authors contributed equally to the present work.
& The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal
doi:10.1093/eurheartj/ehv579
 European Heart Journal Advance Access published November 20, 2015
 by guest on January 13, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
Translational perspective
Fibro-adipose substitution has a double detrimental effect on the myocardium in arrhythmogenic cardiomyopathy (ACM), worsening ar-
rhythmogenesis by creating a non-conductive substrate, and causing ventricular dysfunction leading to heart failure. Notably, to-date no
etiological therapy is available. This work introduces, for the first time, the stromal cardiac compartment as a key player in ACM ventricular
adipose substitution: we demonstrated that cardiac human mesenchymal stromal cells undergo adipogenic differentiation both in ACM
explanted hearts and in culture through a PKP2-dependent mechanism. Cardiac mesenchymal stromal cells constitute a suitable cellular
platform for future mechanistic studies and a potential target for future therapies.
Introduction
Arrhythmogenic cardiomyopathy (ACM) is a genetic disease in
which the ventricular myocardium, predominantly the right ven-
tricle, is progressively substituted by fibro-adipose tissue. Arrhyth-
mogenic cardiomyopathy is associated with severe ventricular
arrhythmias, sudden death, and progressive heart failure.
Fibro-adiposis is the hallmark of the disease; it typically starts from
the epicardium at the ‘triangle of dysplasia’ and progresses toward
the endocardium. Arrhythmogenic cardiomyopathy has a double
pathologic phenotype: arrhythmias and ventricular dysfunction.1
The pathogenic mechanisms for both phenotypes are unclear. Al-
though a primary electrical cause of arrhythmias involving sodium
channels2,3 and connexins4,5 has been proposed,2,6 fibro-fatty sub-
stitution may worsen the condition of patients’ by creating non-
conducting tissue. Moreover, progressive adipocyte deposition
leads to loss of cardiac contractility and ultimately heart failure.
The disease usually has an autosomal dominant transmission with
variable penetrance and expressivity. Rare recessive forms of
ACM occur in conjunction with skin manifestations. Approximately
50% of symptomatic individuals harbour a mutation in one of the
genes of the five major members of the cardiac desmosome: DSP
(desmoplakin),7 PG (plakoglobin),8 PKP2 (plakophilin2),9 DSG2
(desmoglein2),10 and DSC2 (desmocollin2).11 Desmosomes are
complex cellular junctions found mainly in epidermal cells and in
cardiac myocytes.12 Non-desmosomal genes TGFB3, TMEM43,
LMNA, DES, TTN, PLN, CTNNA3, RYR2, and a number of other loci
have also been associated with ACM.13
It has been suggested that defective desmosomes14 cause stretch-
induced cardiomyocyte death15 and impair intracellular signaling
that determines cell fate.16,17 As a consequence, a cell differentiation
hypothesis has been formulated to explain the fibro-adipose re-
placement, involving the inhibition of canonical WNT/b-catenin sig-
naling, an important regulator of myogenesis vs. adipogenesis.17–20
A key question in ACM pathogenesis is the cellular origin of ex-
cess adipocytes. The signal for enhanced fibro-adiposis is likely to
originate from cells that express desmosomes. Mature cardiomyo-
cytes,21 – 23 second heart field cardiovascular progenitor cells
(c-KIT/SCA1),24 or sub-epicardial progenitor cells25 are the most
extensively studied candidates.
Mesenchymal stromal cells (MSC) are supportive cells found in
many tissues.26 They are multipotent and, under appropriate stimuli,
can differentiate into osteoblasts, condroblasts, and adipocytes.26,27
Mesenchymal stromal cells are characterized by the expression of
mesenchymal surface antigens such as CD44, CD105, CD29, and
CD90. In our laboratory, a population of cardiac mesenchymal
stromal cells (C-MSC) isolated from adult human auricles have
been characterized.27 In a normal adult heart, cardiomyocytes only
represent 30% of the total cell number. The remaining 70% consists
of cells other than cardiomyocytes, among which C-MSC are the vast
majority.28 Cardiac mesenchymal stromal cells play a critical role in
maintaining normal cardiac function, as well as in cardiac remodelling
during pathological conditions.29 Mesenchymal stromal cells switch
between osteoblast and adipocyte differentiation has been reported
as a causative mechanism of osteoporosis.30
The present study addresses, for the first time, the role of C-MSC
in ACM adipose substitution in human hearts. We provide evidence
that in ACM hearts cells differentiating into adipocytes express mes-
enchymal markers and C-MSC isolated from human ACM hearts ex-
press desmosomal genes and are more prone to accumulate fat
(lipogenesis) and specifically differentiate into adipocytes compared
with C-MSC from control hearts.
Methods
Detailed/additional methods are presented in Supplementary material
online.
Ethical statement
This study complies with the declaration of Helsinki. Arrhythmogenic
cardiomyopathy (ACM) patients’ samples use for research was ap-
proved by Centro Cardiologico Monzino and La Sapienza University
Ethic Committees. Samples from patients not affected by arrhythmo-
genic cardiomyopathy (NON-ACM) were obtained from cadaveric do-
nors from Fondazione Banca dei Tessuti di Treviso.
Cardiac mesenchymal stromal cells culture
and adipogenic differentiation
Cardiac mesenchymal stromal cells were isolated, cultured, and char-
acterized as previously reported.27 Adipogenic differentiation was
obtained using adipogenic medium27 for 72 h or 1 week. Fat accumula-
tion was tested by Oil Red O (ORO) or Nile Red staining; adipogenesis
was tested by anti-Perilipin1 (PLIN1) antibody staining.
Gene expression analysis
qRT-PCR was performed in duplicate using 10 ng cDNA obtained after
total RNA extraction with TRIzol, treatment with Dnase I, and reverse
transcription with Superscript III according to manufacturer’s instructions.
Primer sequences are reported in Supplementarymaterial online, Table S4.
Protein expression analysis
Western blots were performed by standard procedures, after total pro-
tein extraction by Laemmli buffer lysis, target proteinswere detectedwith
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Table 1 Clinical characteristics of enrolled patients, classified by major or minor arrhythmogenic cardiomyopathy diagnostic criteria33
Sample type ACM
patient
ID
Sex
age
Type/age of first
manifestation
Dysfunction and
structural
alterations
Tissue
characterization
of wall
Repolarization
ab.
Depolarization/
conduction ab.
Arrhythmias Family
history
Mutations in
ACM-associated
genes
Echo CMR AG
EH FFPE H1 F 42 VT/34 Major Major n.a. Major Major Major Major Neg. n.a.
H2 F 37 Sincope, sustained
VT/33
Major Major n.a. Major Neg. Minor Minor Major DSP: c.4198C. T
H3 M 53 VT/11 Major n.a. n.a. Major Neg. Minor Major Neg. n.a.
Biopsy FFPE B1 F 37 Palpitations,
polymorphic
PVC/37
Minor Minor n.a. Major Neg. Neg. Minor Neg. Nonea
B2 M 48 Sustained VT/34 Minor Major n.a. Major Neg. Neg. Major Neg. None
B3 M 26 ECG– inverted T
waves/26
Neg. Major n.a. Minor Major Neg. Minor Neg. None
Biopsy C-MSC B4 M 54 Cardiac arrest/50 Neg. Minor n.a. Major Neg. Neg. Major Major PKP2: c.2013delC
B5 M 44 Cardiac arrest/42 Minor Major n.a. Major Major Neg. Major Major PKP2: c.1643delG
B6 M 41 PVC/32 Major n.a. Major Not conclusive Major Neg. Minor Major PKP2: c.1881delC not
prev. described
B7 M 51 Sustained VT/50 Minor Minor n.a. Major Minor Neg. Major Neg. None
B8 M 57 Polymorphic PVC/
56
Neg. Minor n.a. Minor Neg. Minor Minor Neg. None
B9 F 38 ECG- inverted T
waves/37
Neg. Neg. n.a. Major Minor Neg. Minor Major PKP2: c.2013delC
FFPE, formalin-fixed, paraffin-embedded tissue section; Echo, 2D-echocardiography; CMR, cardiac magnetic resonance; AG, angiography; n.a., not available; PVC, premature ventricular contractions; VT, ventricular tachycardia; EH, explanted
heart; neg., negative; ab., abnormalities.
aOnly PKP2 was examined.
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primary antibodies PKP2, PG, DSP1/2, DSG2, DSC2, PPARg, PLIN1,
FABP4, and GAPDH (see Supplementary material online, Table S3).
Plakophilin2 overexpression
Cardiac mesenchymal stromal cells were transfected with control GFP
or wild-type PKP2-GFP vector30 using the Neon Transfection System.
Cardiac mesenchymal stromal cells and heart
section immunofluorescence
Cells were fixed with 4% paraformaldehyde, paraffin was removed
from embedded sections and antigen unmasking was performed. Pri-
mary and secondary antibodies staining was carried out in 2%
serum.31
Statistical analysis
Descriptive variables are reported as mean+ standard deviation. Re-
sults were analysed by two-tailed Student’s t-test, Pearson’s correlation
test or Fisher’s exact test. Benjamini Hochberg correction was applied
when appropriate. Results were considered statistically significant at
P,0.05.
Results
Cells differentiating into adipocytes in
arrhythmogenic cardiomyopathy human
hearts are of mesenchymal origin
To understand the cellular origin of excess adipocytes in ACM hearts,
we performed double staining with PLIN1 antibody and mesenchymal
markers CD29 and CD105 on serial slices of three ACM explanted
hearts (H1–3, Table 1; Figure 1) and three autopsied control hearts
(see Supplementary material online, Table S1). PLIN1 is a protein, spe-
cifically expressed in adipocytes,32 surrounding lipid droplets. We ob-
served contour staining of large lipid drops of mature adipocytes, as
well as small droplets which eventually fuse duringmaturation of imma-
ture adipocytes. We found that all of these differentiating cells express
the mesenchymal markers CD29 and CD105 (Figure 2A). We did not
detect PLIN1 staining in cells expressing a-sarcomeric actin (aSARC;
Figure 2B), which suggests that mature cardiomyocytes are not the
source of adipogenesis. Further, since the involvement of cardiac pro-
genitor cells was suggested,20 we looked for immature adipocytes ex-
pressing the c-KIT marker. We detected occasional PLIN1 and c-KIT
Figure 1 Characteristics of an arrhythmogenic cardiomyopathy patient (H1) who underwent heart transplant. (A) Twelve-lead electrocardio-
gram of a patient with an advanced form of arrhythmogenic cardiomyopathy, recorded 2 years before heart transplant, characterized by sinus
rhythm, complete right bundle branch block, ST-T wave abnormalities in leads II, III, aVF, V1–V4 where an 1wave can also be identified. Frequent
monomorphic premature ventricular beats originating from the inferior right ventricular wall are recorded. (B) Explanted heart of a late-stage
arrhythmogenic cardiomyopathy patient, with biventricular involvement. Severe fibro-fatty infiltration is visible in the right ventricle, which is di-
lated with thin walls. A high-voltage implantable cardioverter defibrillator lead is visible in the right ventricular chamber. (C) Histological prepar-
ation of right ventricle tissue sample of the explanted heart (haematoxylin and eosin staining). The scale bar indicates 100 mm.
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double-positive differentiating cells (see Supplementary material on-
line, Figure S1). CD29 and CD105-positive differentiating cells were
also found in left ventricle (LV) samples of patients H1 andH2, showing
biventricular ACM, whereas only few cells were observed in control
hearts (data not shown). Moreover, to verify that pre-adipocytes are
of mesenchymal origin even at early phases of the disease, we obtained
paraffin sections (FFPE) of biopsies from three patients withmild forms
of ACM (B1–3, Table 1). We found fewer pre-adipocytes than in ex-
planted hearts; however, all stained positive for mesenchymal markers
(see Supplementary material online, Figure S2A and B). In addition, we
did not detect any PLIN1-positive cells co-staining for c-KIT (see Sup-
plementary material online, Figure S2C).
Cardiac mesenchymal stromal cells can be
obtained from arrhythmogenic
cardiomyopathy hearts and studied in vitro
To verify whether the MSC cardiac population may represent the
source of excess adipocytes in ACM hearts, C-MSC were isolated
from right ventricular endomyocardial bioptic samples from six
ACM patients (B4–9, Table 1) and from five control subjects’ right
ventricular autopsy samples (see Supplementary material online,
Table S1). The biopsy procedure was performed for diagnostic pur-
pose (Figure 3E and F ) in patients with electrocardiogram (ECG;
Figure 3A) and cardiac magnetic resonance (CMR; Figure 3B and Sup-
plementary material online, Videos A and B) findings suggestive of
ACM. Bioptic samples for C-MSC isolation (Figure 3D) were acquired
in the area adjacent to the electro-anatomical scars (Figure 3C), with-
out evidence of adipose substitution.
NON-ACM and ACM C-MSC were selected and characterized
for morphology and expression of mesenchymal antigens27 (see
Supplementary material online, Figure S3 and Table S2).
Cardiac mesenchymal stromal cells
express desmosomal genes and proteins
Cardiomyocytes21–23 or their progenitors24 have been previously
studied in ACM as the only cardiac cell types expressing desmosome
genes. As shown by gene expression analysis in Figure 4A, we de-
monstrated that desmosomal genes PKP2, JUP, DSG2, DSP, and
DSC2 are detectable in isolated C-MSC, and expressed at similar le-
vels in ACM and control cells. Whole ventricle tissue samples were
examined as positive controls. This result raised the possibility that
C-MSC may be directly affected by ACM-causing mutations. West-
ern blot analysis confirmed that PKP2, PG, DSP, and DSC2 proteins
were expressed in ACM and control C-MSC. Plakophilin2 expres-
sion was lower in ACM C-MSC (Figure 4B).
Arrhythmogenic cardiomyopathy cardiac
mesenchymal stromal cells show more
propensity than controls to differentiate
into adipocytes
When cultured in adipogenic medium (72 h and 1 week),27 ACM
C-MSC accumulated lipids earlier and in significantly higher amounts
than NON-ACM control cells (Figure 5). Indeed, after 72 h in adipo-
genic medium, lipid content, quantified by ORO staining, showed
statistically different values between NON-ACM and ACM cells
Figure 2 Cells undergoing adipogenic differentiation in arrhythmogenic cardiomyopathy hearts express the mesenchymal markers CD29 and
CD105 and not the cardiomyocyte marker a-sarcomeric actin. Immunostaining of FFPE sections of explanted hearts from three arrhythmogenic
cardiomyopathy patients. Nuclei are stained with Hoechst 33258. (A) PLIN1 antibody marks lipid drop membranes identifying pre-adipocytes and
CD29 (upper panel), or CD105 (lower panel) as used as mesenchymal markers. The scale bar indicates 10 mm. (B) Transversal (upper panel) and
longitudinal (lower panel) sections are immunostained with PLIN1 and a-sarcomeric actin for cardiomyocytes. The scale bar indicates 20 mm.
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(24.65+3.32 vs. 66.97+12.48 arbitrary units, P, 0.001). This dif-
ference persisted after 1 week in adipogenic medium (Figure 5B;
60.83+16.67 vs. 137.40+28.11 a.u., P ¼ 0.001).
The expression of genes involved in adipogenesis or specific for
adipocytes was then examined. We found that the enhanced ex-
pression of PPARg, ADIPOQ, FABP4, and PLIN1 after 72 h in adipo-
genic medium was significantly more pronounced in ACM than
in NON-ACM C-MSC (Figure 6A). This result was confirmed by
western blot for PPARg, FABP4, and PLIN1 (Figure 6C). As shown
in Figure 6B, a positive correlation exists between ADIPOQ and
PLIN1 expression and lipid accumulation analysed by ORO staining
(r ¼ 0.874 and r ¼ 0.884, respectively).
In contrast, the anti-adipogenic gene CTGF34 and the cell-cycle
regulator CCND1 were expressed at significantly lower levels in
ACM samples than in NON-ACM controls (Figure 6A).
To test the involvement of the WNT pathway, we treated ACM
C-MSC with 6-bromoindirubin-3′-oxime (BIO), a drug that inhibits
GSK3b20: C-MSC cultured with BIO showed a partial (31.25%)
reduction in accumulated lipid droplets (P ¼ 0.002) and a 92.24%
reduction in ADIPOQ expression (P ¼ 0.045; see Supplementary ma-
terial online, Figure S4). Notably, PG showed a preferential nuclear
localization in ACM C-MSC and a predominant localization in the
cytoplasm and at cell–cell junctions in NON-ACM C-MSC (see
Supplementary material online, Figure S5).
Lipid accumulation and transcriptional
rearrangements in arrhythmogenic
cardiomyopathy cardiac mesenchymal
stromal cells are dependent on PKP2
deficiency
In order to establishwhether the diminished expression of PKP2 plays a
causal role in lipid accumulation, ACMC-MSC were transfected either
with a plasmid encoding PKP2, or with an empty control vector. PKP2
overexpression was confirmed both at gene and protein levels
(Figure 7A). After 72 h in adipogenic medium, cells were examined
Figure 3 Representative diagnostic findings of an arrhythmogenic cardiomyopathy patient (B7) who underwent biopsy. (A) Twelve-lead elec-
trocardiogram is characterized by sinus rhythm, normal conduction, negative T waves in V1–V3 leads. A ventricular premature beat originating
from the right ventricular outflow tract is shown. (B) Cardiac magnetic resonance: four-chamber long axis (B, online videoA) and short-axis (B
′
,
online videoB) steady-state free procession sequences of left ventricle showed dilated rigth ventricle with multiple diastolic bulging in the subtri-
cuspid region (arrows). The T1-weighted image (B′ ′) and post-contrast late gadolinium enhancement sequence (B′ ′ ′) show high-intensity signal
suggesting fibro-adipose infiltration of the right ventricular-free wall (arrows). (C) Three-dimensional electroanatomical bipolar map of the right
ventricular (endocardial aspect): normal signals are recorded over the entire right ventricular chamber (preserved voltage amplitude, .1.50 mV,
purple), excepted from a portion of the anterior wall that is characterized by low-amplitude voltage (,1 mV, blue-yellow) with a small area of
heterogeneous dense scar (,0.5 mV, red). (D) Endomyocardial biopsy bright field image. All biopsies used for cardiac mesenchymal stromal cells
isolation were acquired in the area adjacent to the electro-anatomical scar and adipocytes are not evident at gross examination. (E) Histological
preparation (haematoxylin and eosin staining) of a bioptic sample acquired in the pathological area, for diagnostic purposes. Confirmation of ar-
rhythmogenic cardiomyopathy diagnosis is given by the evidence of large fibro-fatty substitution. (F) Histological preparation (Masson-trichrome
staining) of a bioptic sample. Fibrotic tissue is evident in blue beside adipocytes (white round circles). All the scale bars indicate 100 mm.
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for lipid accumulation and expression of adipogenic genes. Oil Red O
staining showed a significant decrease in the number of
PKP2-overexpressing cells containing lipid droplets when compared
with mock-transfected controls (Figure 7C; 21.33%+ 4.65 vs.
32.57%+4.71, P ¼ 0.047). Moreover, PKP2-overexpressing C-MSC
showed a 98.10% and a 29.80% decrease in ADIPOQ (P¼ 0.034) and
PPARg (P ¼ 0.032) expression, respectively (Figure 7B). Finally, we con-
firmed that lipid accumulation is dependent on PKP2 deficiency by using
a specific siRNA during adipogenic induction. Indeed, silencing of PKP2
(see Supplementary material online, Figure S6A) was accompanied by a
significant increase in lipid accumulation (15.87+6.99 vs. 38.66+
16.91; P¼ 0.009; see Supplementary material online, Figure S6B).
Arrhythmogenic cardiomyopathy cardiac
mesenchymal stromal cells undergo
adipogenesis
To verify that the accumulation of lipid droplets is associated with
C-MSC differentiation to adipocytes and not to mere lipogenesis,
we analysed the expression of PLIN1 by qRT-PCR, western blot
(Figure 6A and C ) and immunofluorescence (Figure 8A). Indeed,
ACM C-MSC accumulated lipid surrounded by adipocyte-specific
PLIN1 protein. ACMC-MSC cultured in adipogenic medium stained
with anti-PLIN1 antibody are phenotypically very similar to the
adipogenic differentiating cells detected in ACM patients’ hearts
(Figures 2 and 8B). Furthermore, ACM C-MSC maintained the mes-
enchymal marker CD29 during adipogenesis in vitro (see Supple-
mentary material online, Figure S7).
Discussion
To date, ACM has been considered a disease confined to contractile
cells even if there is no conclusive experimental evidence to support
this hypothesis. To our knowledge, this work is the first demonstra-
tion that desmosomal genes are expressed in C-MSC, besides car-
diomyocytes, and epithelial cells.12,35,36 Cardiomyocytes have been
shown to accumulate lipid in different models, but each of them
Figure 4 Expression of desmosomal genes and proteins. ACM: samples from patients affected by arrhythmogenic cardiomyopathy; NON-
ACM: samples from patients not affected by arrhythmogenic cardiomyopathy. (A) Desmosomal genes are expressed in ventricular mesenchymal
stromal cells. Cardiac mesenchymal stromal cells RNA extracts either from patients not affected or affected by arrhythmogenic cardiomyopathy
(n ¼ 3 vs. n ¼ 4) genes threshold cycles (Ct) with respect to the housekeeping gene GAPDH are examined. Total ventricle RNA extracts (n ¼ 3)
from patients not affected by arrhythmogenic cardiomyopathy are also reported as positive controls. (B) Desmosomal proteins are expressed in
cardiac mesenchymal stromal cells, and PKP2 is expressed at a lower level in arrhythmogenic cardiomyopathy cardiac mesenchymal stromal cells.
PKP2, PG, DSP1/2, DSG2, DSC2, and house-keeping gene GAPDH western blots of protein extracts of cardiac mesenchymal stromal cells from
patients not affected by arrhythmogenic cardiomyopathy (n ¼ 3) and affected (n ¼ 4) are shown. Total ventricle lysates (n ¼ 2) from patients not
affected by arrhythmogenic cardiomyopathy are shown as positive controls. Densitometry, relative to the loading control GAPDH, is shown in the
graphs, normalized for the expression of samples from patients not affected by arrhythmogenic cardiomyopathy.
Cardiac mesenchymal stromal cells in arrhythmogenic cardiomyopathy Page 7 of 12
 by guest on January 13, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
exhibit shortcomings. Indeed, induced pluripotent stem cells (iPSC)-
derived cardiomyocytes are a promising patient-specific tool to
study ACM as they accumulate lipids.22,23,37 Ongoing studies might
overcome the lack of terminal differentiation in cardiomyocytes de-
rived from iPSC, and the presence of residual partially repro-
grammed cells.38 Evidence of desmin and vimentin expression in
cells differentiating into adipocytes in heart tissue of a suspected
ACM patient has been reported21; however, these proteins are
not expressed exclusively in cardiomyocytes and adipocytes. An-
other study claimed that neutral lipids accumulated in ACM right
ventricular myocardial tissue38; despite this, there was no evidence
of myocardial cell differentiation into adipocytes. Finally, transgenic
murine models of ACM, expressing different disease-causing muta-
tions under the aMHC promoter,6,16 showed the accumulation of
adipocytes in the heart, but trans-differentiation of cardiomyocytes
into adipocytes was not investigated. In human ACM specimens, we
found neither PLIN1-positive lipid droplets accumulating in cardio-
myocytes nor aSARC staining in immature adipocytes: this rules out
a direct trans-differentiation of cardiomyocytes into adipocytes.
Nevertheless, we cannot exclude cardiomyocyte lipogenesis, as
previously described.39
In the present work, we investigated whether the non-contractile
cardiac stromal compartment is the cellular source contributing to
excess adipocytes in ACM hearts. Cardiac mesenchymal stromal cells
are the most abundant cell type in the heart, have a mesenchymal
origin, and exert a fundamental role in maintaining cardiac structural
and functional homeostasis in physiologic and pathologic condi-
tions.29 Importantly, upon appropriate culture conditions C-MSC
can differentiate into adipocytes.27 Therefore we hypothesized and
demonstrated that when affected by ACM mutations, C-MSC en-
hance their ability to accumulate lipids, differentiate into adipocytes,
and play a role in fibro-fatty substitution.
Based on the obtained evidence, we advocate C-MSC as a novel
non-contractile cell type contributing to excess adipocyte accumu-
lation in ACM. PKP2-silenced murine epicardial cells were so far the
best characterized non-contractile cell type as a putative source of
lipid accumulation.35,40 Epicardial cells have been recognized as se-
cond heart field-derived progenitors of a large fraction of non-
myocyte heart cells, including fibroblasts.41 Epicardial cells silenced
for PKP2 were shown to be able to accumulate more lipid than con-
trol epicardial cells (EPC).35 We believe that this observation is not
conflicting with our results. Epicardial cells may undergo epithelial-
mesenchymal transition, thus retaining, as adult MSC, the ability to
accumulate lipid in a PKP2-dependent manner.
Resident cardiac stem cells (c-KIT/SCA1) from PG transgenic mice
have been indicated by Lombardi et al.20 as a source of adipocytes.
Figure 5 Cardiac mesenchymal stromal cells obtained from arrhythmogenic cardiomyopathy patients (ACM), cultured in adipogenic medium,
accumulate more lipid droplets than control cardiac mesenchymal stromal cells (NON-ACM). Representative images of cardiac mesenchymal
stromal cells from bioptic samples of patients affected and not affected by arrhythmogenic cardiomyopathy, cultured for 72 h and 1 week in adi-
pogenic medium, stained with Oil Red O (ORO; n ¼ 6 vs. n ¼ 4). The scale bar indicates 50 mm. Quantification of the luminance of the 255 red
staining is reported on the right: intensity is expressed in arbitrary units.
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We also found occasional c-KIT positive cells undergoing adipogenic
differentiation in ACM patients’ hearts; however, in our opinion, the
rates were too low to account for a major role in lipid accumulation.
We have previously shown that c-KIT positive cells can express
mesenchymal markers,42 but they represent only the 0.5–1.5% of
isolated C-MSC (see Supplementary material online, Figure S1 and
Table S2 and27). Therefore, the diffuse, homogeneous adipogenic
differentiation of the whole ACM C-MSC population observed
in vitro argues against a major direct contribution of cardiac progeni-
tor cells in the development of fibro-adipose substitution in ACM.
Plakoglobin predominant nuclear staining in cultured C-MSC is
consistent with previous findings in other cell types,20,37 even if
this phenomenon is still controversial in vivo.43 The partial rescue
of the lipid accumulation phenotype in C-MSC treated with BIO is
suggestive of WNT pathway involvement in ACM, although not to
the exclusion of the contributions from other mechanisms.
Notably, C-MSCmay be viewed as a novel cell platform for study-
ing ACM in vitro. Different cellular models of disease pathogenesis
have been previously proposed, mainly focused on the contractile
component of the heart: PKP2-silenced cardiomyocytes,3,40 murine
DSP-deficient HL1 or mouse cardiomyocytes,19 PG transgenic
mouse c-KIT/SCA1 cells,20 and recently different lines of iPSC-
derived cardiomyocytes.22,23,37 However, these models have specif-
ic intrinsic problems, including the lack of endogenous genetic mu-
tation, the non-human cell origin, possible reprogramming biases, or
unsuitability for high-throughput screenings. Mutated and control
C-MSC are primary cells directly obtained from human ventricular
tissue, easy to isolate and amplify, carrying the whole patient’s gen-
etic setting (ACM mutation and background). Therefore, we think
that C-MSC are suitable tools for disease modelling.
Notwithstanding the relevance of substrate insults in generating
or worsening the arrhythmic phenotype of ACM, recent reports
highlight ACM as a primary electrical cardiac disease.2 – 4,6,44 Al-
though we have observed that in growth conditions Cx43 expres-
sion levels and cellular localization (see Supplementary material
online, Figure S8) are similar in ACM and NON-ACM C-MSC, fu-
ture studies are needed to establish whether differentiating
C-MSC can contribute to modulate cell survival/death, as well as
functional properties of cardiomyocytes,45 and of other cardiac
cell types.
In conclusion, the present article reports unprecedented evi-
dence that C-MSC are a source of adipocytes in ACM heart tissue
and that ACM-derived primary C-MSC differentiate into adipocytes
in vitro.
Figure 6 Arrhythmogenic cardiomyopathy cardiac mesenchymal stromal cells in adipogenic medium show higher transcription of adipogenic
genes and proteins and a lower transcription of anti-adipogenic and proliferation genes, compared to control cells. ACM: samples from patients
affected by arrhythmogenic cardiomyopathy; NON-ACM: samples from patients not affected by arrhythmogenic cardiomyopathy. (A) Compari-
son of transcript abundance (genes threshold cycles [Ct] with respect to the house-keeping gene GAPDH) between RNA extract of cardiac mes-
enchymal stromal cells from patients not affected and affected by arrhythmogenic cardiomyopathy (n ≥ 4), after 72 h culture in adipogenic
medium. (B) ADIPOQ and PLIN1 gene expression positively correlates with lipid accumulation (Oil Red O staining) in arrhythmogenic cardiomy-
opathy samples. (C) Comparison of PLIN1, PPARg, and FABP4 protein abundance between protein extracts of cardiac mesenchymal stromal cells
from patients not affected by arrhythmogenic cardiomyopathy (n ¼ 3) and from arrhythmogenic cardiomyopathy patients (n ¼ 5), after 72 h cul-
ture in adipogenic medium. Quantification of the mean protein abundance relative to GAPDH, and normalized for values of samples from patients
not affected by arrhythmogenic cardiomyopathy, is shown in the graphs.
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Study limitations
The variability we observed among cells derived from different pa-
tients, both in lipid accumulation and in gene expression, may at least
partially correlate with patient clinical presentation and genetic sta-
tus. Though limited by the small sample size, an analysis of C-MSC
ORO staining intensities stratified by genotype indicated that cells
from PKP2mutation carriers have a higher predisposition to lipid ac-
cumulation than C-MSC from patients without mutations in known
ACM-related genes (P ¼ 0.058). Further, all PKP2 mutation carriers
biopsies reached the major diagnostic criterion of substantial
fibro-fatty replacement of myocardium. These observations, if vali-
dated in studies with larger cohorts, may complete arrhythmic
phenotype–genotype correlations reported by Bao and collea-
gues,46 who demonstrated that mutation carriers (in particular of
PKP2) are subject to spontaneous and induced VT more often
than patients without mutations.
We obtained C-MSC only from PKP2 mutation carriers or from
patients with no mutations in known ACM-associated genes
(Table 1). Therefore, our results need to be tested in patients
with other desmosomal or non-desmosomal mutations.
Figure 7 Arrhythmogenic cardiomyopathy cardiac mesenchymal stromal cells lipid accumulation is dependent on the expression of PKP2. Ar-
rhythmogenic cardiomyopathy cardiac mesenchymal stromal cells (ACM; n ¼ 3) were transfected with an empty vector (EV) or a vector over-
expressing PKP2 (PKP2 OE). (A) Increased expression of PKP2 gene (left graph) and PKP2 protein (right blot) in the PKP2 OE cells compared with
mock-transfected cells, 72 h after transfection. (B) Comparison of transcript abundance between arrhythmogenic cardiomyopathy cardiac mes-
enchymal stromal cells transfected either with the empty or the PKP2 expression vector, after 72 h culture in adipogenic medium. (C) Represen-
tative Oil Red O (ORO) staining images of arrhythmogenic cardiomyopathy cardiac mesenchymal stromal cells transfected either with the empty
or the PKP2 expression vector, cultured for 72 h in adipogenic medium. The graph shows the percentage of cells containing at least one lipid
droplet. The scale bar indicates 50 mm.
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Not having access to LV bioptic samples of ACM patients, we
were unable to explore possible differences in adipogenic propen-
sity between the right and left ventricles.
Supplementary material
Supplementary material is available at European Heart Journal online.
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